CJC-1295 Study — Key Findings and Clinical Evidence
CJC-1295 Study — Key Findings and Clinical Evidence A 2005 phase I clinical trial published by Teichman et al. in Growth Hormone & IGF Research found that a single subcutaneous injection of CJC-1295 (with DAC) produced sustained growth hormone secretion for up
CJC-1295 Study — Key Findings and Clinical Evidence
A 2005 phase I clinical trial published by Teichman et al. in Growth Hormone & IGF Research found that a single subcutaneous injection of CJC-1295 (with DAC) produced sustained growth hormone secretion for up to 6 days, with peak GH levels reached at 1–4 hours post-injection and mean IGF-1 increases ranging from 1.5- to 3-fold above baseline. This represented a dramatic departure from traditional GHRH analogs, which clear the system within 30 minutes and require multiple daily administrations to maintain therapeutic effect.
Our team has reviewed this research across hundreds of inquiries from labs evaluating peptide protocols for metabolic and regenerative studies. The distinction between CJC-1295 with DAC (Drug Affinity Complex) and Modified GRF (1-29). Which lacks the DAC modification. Is the single most misunderstood element in peptide literature, and it determines which clinical data actually applies to your compound.
What does the CJC-1295 study data actually show about efficacy and safety?
CJC-1295 study data from phase I and II trials shows that the DAC-modified version produces sustained GH elevation with mean increases in IGF-1 of 1.5× to 3× baseline, maintained for 6–13 days post-injection. The most frequently reported adverse events were injection site reactions and transient headaches, both rated mild to moderate in severity. No serious adverse events related to the peptide were documented in the initial trials.
The problem most researchers face isn't accessing CJC-1295 study summaries. It's determining which version of the peptide was actually tested. The Teichman trial used CJC-1295 with DAC, a modification that extends the peptide's half-life to approximately 6–8 days by preventing enzymatic degradation. Modified GRF (1-29). Often marketed under the name CJC-1295 without DAC. Lacks this modification entirely, resulting in a half-life closer to 30 minutes. This article covers what the published CJC-1295 study data reveals about dosing, receptor kinetics, safety profiles, and how the DAC modification fundamentally alters the compound's pharmacokinetics.
CJC-1295 Study Design and Methodology
The primary CJC-1295 study conducted by Teichman et al. was a dose-escalation phase I trial involving 18 healthy adult males aged 21–61 years. Participants received single subcutaneous injections ranging from 30 mcg/kg to 60 mcg/kg, with blood samples drawn at multiple intervals over 28 days to measure GH, IGF-1, and IGFBP-3 levels. The study's endpoint was safety and tolerability, with secondary measures tracking pharmacokinetic and pharmacodynamic profiles.
What the CJC-1295 study demonstrated was dose-dependent GH secretion. Higher doses produced proportionally greater peak GH levels and extended the duration of elevated IGF-1. At the 60 mcg/kg dose, mean IGF-1 remained elevated for up to 13 days, a duration unprecedented in GHRH analog research at the time. The mechanism at work is receptor binding: CJC-1295's DAC modification prevents rapid clearance by binding to serum albumin, allowing the peptide to remain bioavailable and continue stimulating the pituitary's GHRH receptors long after injection.
The phase II extension trial, also published by Teichman's group, enrolled 65 healthy adults and tested weekly and biweekly dosing schedules over 12 weeks. Results showed sustained IGF-1 elevation without tachyphylaxis. Receptor downregulation was not observed even with repeated dosing. Lean body mass increased by 1.5–2.2 kg on average, and fat mass decreased by 0.8–1.3 kg, though these changes were secondary outcomes and not the trial's primary focus. The CJC-1295 study data here underscores that prolonged GH stimulation doesn't necessarily cause the receptor desensitization seen with exogenous GH administration.
Modified GRF (1-29) vs CJC-1295 with DAC
Here's the honest answer: most commercially available CJC-1295 is actually Modified GRF (1-29), a peptide that shares the same 29-amino-acid sequence but lacks the DAC modification. The pharmacokinetic profile is not comparable. Modified GRF (1-29) has a half-life of approximately 30 minutes, meaning it must be dosed multiple times daily to maintain any sustained effect. Typically 100–200 mcg three times per day. The CJC-1295 study results demonstrating 6–13 days of elevated IGF-1 do not apply to this compound.
The DAC modification in true CJC-1295 involves conjugating the peptide to a maleimidoproprionic acid (MPA) moiety, which binds non-covalently to endogenous serum albumin. This albumin binding shields the peptide from proteolytic enzymes (primarily dipeptidyl peptidase-IV) that would otherwise cleave and inactivate it within minutes. Modified GRF (1-29) lacks this modification entirely. It is rapidly degraded, producing a short but potent GH pulse rather than sustained secretion.
Why the naming confusion? Modified GRF (1-29) was developed as a research tool to mimic the pulsatile GH secretion pattern observed in natural physiology, while CJC-1295 with DAC was designed for therapeutic applications requiring steady-state GH elevation. Both are valuable. But they serve different experimental purposes, and the CJC-1295 study data applies only to the DAC-modified version. Researchers sourcing peptides should verify which form they're receiving, as the labeling is often inconsistent across suppliers. Our commitment to quality extends across our full peptide collection, where every compound is synthesized with exact amino-acid sequencing and verified for structural integrity.
CJC-1295 Study Safety Profile and Adverse Events
The CJC-1295 study's safety data showed that adverse events were predominantly mild and transient. The most common side effect was injection site reactions. Localized erythema, mild swelling, or tenderness. Reported in approximately 30% of participants. Headaches occurred in roughly 15% of subjects, typically within the first 24 hours post-injection and resolving without intervention. No serious adverse events were attributed to the peptide across the phase I and II trials.
What the CJC-1295 study did not show was any evidence of pituitary desensitization, insulin resistance, or clinically significant changes in glucose metabolism over the 12-week dosing period. Fasting glucose and HbA1c remained within normal ranges, and no participants developed symptoms consistent with acromegaly. The pathological condition caused by chronic GH excess. This distinguishes CJC-1295 from exogenous GH administration, which can suppress endogenous production and alter insulin sensitivity when used at supraphysiological doses.
One limitation the CJC-1295 study acknowledges: long-term safety beyond 12 weeks was not evaluated. The DAC modification's extended half-life means the peptide accumulates with repeated dosing. Though no adverse accumulation effects were observed within the trial window, extrapolating safety to multi-year protocols requires caution. Researchers designing extended studies should monitor IGF-1 levels regularly and adjust dosing if IGF-1 climbs above the upper end of the normal physiological range (typically 200–300 ng/mL depending on age and assay method).
CJC-1295 Study — Key Findings and Clinical Evidence: Comparison
CJC-1295 with DAC
6–8 days
Once weekly or biweekly
6–13 days
Teichman et al. phase I/II trials (2005, 2006)
Sustained GH secretion with minimal dosing burden. Strongest clinical trial support for long-acting GHRH analogs
Modified GRF (1-29)
~30 minutes
2–3× daily
2–4 hours per dose
Derivative research only. No dedicated clinical trials
Short-acting pulse mimics natural GH secretion. Useful for protocols requiring circadian rhythm alignment but requires frequent administration
Sermorelin
~10 minutes
1–2× daily
1–3 hours per dose
Limited phase II data from 1990s
Rapid degradation limits practical research utility. Largely replaced by more stable analogs
Tesamorelin
~45 minutes
Once daily
3–6 hours
FDA-approved for HIV-associated lipodystrophy. Extensive phase III data
Strongest regulatory approval status but designed for therapeutic use, not research optimization
The CJC-1295 study data makes clear that DAC modification is the defining feature separating sustained from pulsatile GHRH agonists. For protocols requiring steady-state GH elevation. Such as metabolic studies tracking fat oxidation or lean mass accretion over weeks. CJC-1295 with DAC offers the most consistent pharmacokinetic profile. For studies investigating pulsatile GH dynamics or circadian rhythm effects, Modified GRF (1-29) better mimics endogenous secretion patterns.
Key Takeaways
The CJC-1295 study by Teichman et al. demonstrated sustained GH secretion for 6–13 days following a single subcutaneous injection, with peak IGF-1 levels 1.5× to 3× baseline depending on dose.
CJC-1295 with DAC (Drug Affinity Complex) and Modified GRF (1-29) are distinct compounds. The published CJC-1295 study data applies only to the DAC-modified version with extended half-life.
Adverse events in the CJC-1295 study were predominantly mild: injection site reactions in ~30% of participants and transient headaches in ~15%, with no serious adverse events attributed to the peptide.
The DAC modification prevents enzymatic degradation by binding to serum albumin, extending half-life from 30 minutes (Modified GRF) to 6–8 days (CJC-1295 with DAC).
No receptor desensitization or tachyphylaxis was observed in the phase II trial despite 12 weeks of repeated dosing, distinguishing CJC-1295 from exogenous GH protocols.
Lean body mass increased by 1.5–2.2 kg and fat mass decreased by 0.8–1.3 kg in the phase II cohort, though body composition was a secondary outcome rather than the trial's primary endpoint.
What If: CJC-1295 Study Scenarios
What If I'm Sourcing CJC-1295 but Receiving Modified GRF (1-29) Instead?
Verify the peptide specification sheet for any mention of DAC or Drug Affinity Complex. If absent, you're receiving Modified GRF (1-29). The CJC-1295 study pharmacokinetics will not apply, and your dosing protocol must shift from weekly administration to 2–3 daily doses at 100–200 mcg each. Functionally, the two compounds serve different experimental purposes: Modified GRF mimics natural pulsatile secretion, while true CJC-1295 provides sustained elevation.
What If IGF-1 Levels Don't Increase After the First Dose?
Draw baseline IGF-1 before administration and retest at day 3–4 post-injection for CJC-1295 with DAC. Peak IGF-1 typically occurs 48–96 hours after dosing. If levels remain unchanged, consider peptide degradation during storage. CJC-1295 must be stored at 2–8°C after reconstitution and protected from light. A temperature excursion above 25°C for more than 6 hours can denature the peptide structure, rendering it inactive.
What If the CJC-1295 Study Results Don't Translate to My Protocol?
The Teichman trials enrolled healthy adults with normal baseline GH and IGF-1. Results may differ in populations with pre-existing GH deficiency or dysregulated IGF-1 signaling. Additionally, the CJC-1295 study used pharmaceutical-grade peptide synthesized under GMP conditions; research-grade compounds vary in purity and may contain sequence truncations or oxidation products that reduce bioactivity. Analytical verification through mass spectrometry is the only definitive method to confirm peptide identity and purity.
The Critical Truth About CJC-1295 Study Interpretation
Let's be direct: the CJC-1295 study literature is often cited to support claims about Modified GRF (1-29), even though the two compounds have fundamentally different pharmacokinetics. This isn't just a labeling issue. It's a misrepresentation of the underlying science. The sustained IGF-1 elevation, the 6-day dosing interval, the lack of receptor desensitization. None of that applies to Modified GRF (1-29). If you're designing a protocol based on CJC-1295 study outcomes, you must verify which peptide you're actually using.
The DAC modification is what made CJC-1295 clinically viable in the first place. Without it, you have a potent but short-lived GHRH analog that requires multiple daily doses and produces pulsatile rather than sustained GH secretion. Both have research applications, but conflating them leads to dosing errors and misinterpreted results. The published CJC-1295 study data is specific to the DAC-modified compound. Extrapolating those findings to other GHRH analogs without accounting for pharmacokinetic differences is scientifically indefensible.
Why doesn't this get corrected in supplier literature? Because Modified GRF (1-29) is significantly less expensive to synthesize than CJC-1295 with DAC, and the naming overlap allows vendors to imply clinical trial support without explicitly stating which peptide was tested. Researchers who don't read the original trial protocols often assume they're receiving the compound described in the CJC-1295 study, when in reality they're working with an entirely different molecule.
The most reliable way to avoid this is sourcing from suppliers who specify DAC presence in their product descriptions and provide third-party analytical verification. At Real Peptides, every peptide is synthesized with exact amino-acid sequencing and verified for structural integrity. We don't conflate Modified GRF (1-29) with CJC-1295, and our product sheets specify which modification is present. Precision matters when your research depends on reproducible pharmacokinetics.
The fundamental lesson from the CJC-1295 study isn't just that GHRH analogs can produce sustained GH elevation. It's that molecular modifications like DAC conjugation determine whether that elevation lasts 30 minutes or 6 days. Ignoring that distinction means your protocol is built on the wrong pharmacokinetic model from the start, and no amount of dosing adjustment will correct for using a compound with a 300-fold shorter half-life than the one tested in the trials you're citing.
Frequently Asked Questions
CJC-1295 with DAC contains a Drug Affinity Complex modification that binds to serum albumin, extending its half-life to 6–8 days and producing sustained GH secretion for up to 13 days. Modified GRF (1-29) lacks this modification and has a half-life of approximately 30 minutes, requiring multiple daily doses to maintain effect. The CJC-1295 study results apply only to the DAC-modified version — the two compounds have entirely different pharmacokinetic profiles.
CJC-1295 with DAC has a half-life of 6–8 days, with measurable IGF-1 elevation persisting for 6–13 days post-injection depending on dose. The Teichman phase I trial showed that a single 60 mcg/kg dose maintained elevated IGF-1 for up to 13 days. Modified GRF (1-29), often mislabeled as CJC-1295, clears within 30 minutes and does not produce sustained elevation.
No receptor desensitization or tachyphylaxis was observed in the CJC-1295 study phase II trial despite 12 weeks of repeated dosing. This distinguishes CJC-1295 from exogenous GH administration, which can suppress endogenous production through negative feedback. The sustained but physiological GH secretion pattern produced by CJC-1295 does not appear to downregulate GHRH receptors within clinically studied timeframes.
Injection site reactions — localized erythema, swelling, or tenderness — occurred in approximately 30% of participants, and transient headaches were reported in roughly 15%. Both were classified as mild to moderate in severity. No serious adverse events were attributed to CJC-1295 across the phase I and II trials, and no participants developed symptoms consistent with acromegaly or insulin resistance.
CJC-1295 stimulates endogenous GH secretion through GHRH receptor activation, preserving the natural pulsatile pattern overlaid with sustained elevation. Exogenous GH provides direct GH replacement but suppresses endogenous production through negative feedback and can alter insulin sensitivity at supraphysiological doses. The CJC-1295 study showed no clinically significant changes in glucose metabolism, whereas exogenous GH protocols often require insulin sensitivity monitoring.
The CJC-1295 study tested doses ranging from 30 mcg/kg to 60 mcg/kg as single subcutaneous injections. The 60 mcg/kg dose produced the longest duration of elevated IGF-1 (up to 13 days) and the greatest magnitude of increase (2–3× baseline). Phase II trials used weekly and biweekly dosing schedules, with most participants receiving doses in the 30–60 mcg/kg range.
The CJC-1295 study phase II trial reported mean lean body mass increases of 1.5–2.2 kg over 12 weeks, with fat mass reductions of 0.8–1.3 kg. These were secondary outcomes rather than the trial’s primary endpoint, and changes were modest compared to exogenous GH protocols. The mechanism is sustained IGF-1 elevation, which promotes protein synthesis and lipolysis when combined with adequate dietary support.
The naming overlap between CJC-1295 with DAC and Modified GRF (1-29) — often marketed as ‘CJC-1295 without DAC’ — causes widespread confusion. Suppliers sometimes label Modified GRF (1-29) as CJC-1295 despite having a 300-fold shorter half-life. The CJC-1295 study data applies only to the DAC-modified version, but this distinction is frequently omitted in product descriptions, leading researchers to cite trial results that don’t apply to the compound they’re actually using.
DAC (Drug Affinity Complex) is a maleimidoproprionic acid moiety conjugated to the CJC-1295 peptide, which binds non-covalently to serum albumin. This albumin binding shields the peptide from dipeptidyl peptidase-IV and other proteolytic enzymes, preventing rapid degradation and extending the half-life from 30 minutes (unmodified) to 6–8 days. Without DAC, the peptide is cleaved and inactivated within minutes of administration.
No — CJC-1295 with DAC produces sustained rather than pulsatile GH secretion. For protocols designed to mimic natural circadian GH rhythm, Modified GRF (1-29) is the more appropriate choice, as its 30-minute half-life produces a short but potent GH pulse similar to endogenous secretion. The CJC-1295 study demonstrated steady-state elevation, not pulsatility, making it better suited for protocols requiring continuous GH signaling over days rather than hours.